News Headlines Article

Roche profits up 58% due to low Genentech costs
San Francisco Chronicle

Roche Holding AG, the world’s biggest maker of cancer drugs, reported a 58 percent increase in first-half profit, helped by lower costs associated with the integration of South San Francisco’s Genentech.

Net income rose to $5.2 billion from $3.3 billion a year ago after costs linked to the acquisition of the U.S. biotechnology company weren’t repeated, the Basel, Switzerland, company said Thursday. Roche doesn’t report quarterly profit.